1. Home
  2. CYTK vs BTG Comparison

CYTK vs BTG Comparison

Compare CYTK & BTG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CYTK
  • BTG
  • Stock Information
  • Founded
  • CYTK 1997
  • BTG 2006
  • Country
  • CYTK United States
  • BTG Canada
  • Employees
  • CYTK N/A
  • BTG N/A
  • Industry
  • CYTK Biotechnology: Pharmaceutical Preparations
  • BTG Precious Metals
  • Sector
  • CYTK Health Care
  • BTG Basic Materials
  • Exchange
  • CYTK Nasdaq
  • BTG Nasdaq
  • Market Cap
  • CYTK 5.0B
  • BTG 4.2B
  • IPO Year
  • CYTK 2004
  • BTG N/A
  • Fundamental
  • Price
  • CYTK $50.26
  • BTG $2.82
  • Analyst Decision
  • CYTK Strong Buy
  • BTG Buy
  • Analyst Count
  • CYTK 17
  • BTG 3
  • Target Price
  • CYTK $82.00
  • BTG $4.02
  • AVG Volume (30 Days)
  • CYTK 1.9M
  • BTG 32.5M
  • Earning Date
  • CYTK 02-27-2025
  • BTG 02-19-2025
  • Dividend Yield
  • CYTK N/A
  • BTG 5.69%
  • EPS Growth
  • CYTK N/A
  • BTG N/A
  • EPS
  • CYTK N/A
  • BTG N/A
  • Revenue
  • CYTK $3,219,000.00
  • BTG $1,902,030,000.00
  • Revenue This Year
  • CYTK N/A
  • BTG N/A
  • Revenue Next Year
  • CYTK $754.18
  • BTG $43.26
  • P/E Ratio
  • CYTK N/A
  • BTG N/A
  • Revenue Growth
  • CYTK N/A
  • BTG N/A
  • 52 Week Low
  • CYTK $40.53
  • BTG $2.20
  • 52 Week High
  • CYTK $81.36
  • BTG $3.50
  • Technical
  • Relative Strength Index (RSI)
  • CYTK 58.40
  • BTG 68.20
  • Support Level
  • CYTK $45.05
  • BTG $2.58
  • Resistance Level
  • CYTK $48.30
  • BTG $2.62
  • Average True Range (ATR)
  • CYTK 2.80
  • BTG 0.10
  • MACD
  • CYTK 0.61
  • BTG 0.04
  • Stochastic Oscillator
  • CYTK 86.80
  • BTG 78.57

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

About BTG B2Gold Corp Common shares (Canada)

B2Gold Corp is an international, low-cost, senior gold mining company. It has three operating open-pit gold mines in Mali, Namibia, and the Philippines and numerous exploration projects across four continents. Other significant assets include the Gramalote and Kiaka gold projects. The company focuses on acquiring and developing interests in mineral properties with a primary focus on gold deposits as gold production forms all its revenue. There is no dependence on a particular purchaser because the gold is sold into a global market. The company's reportable operating segments include its mining operations and development projects, namely Fekola; Masbate; Otjikoto; the Goose Project, and other mineral properties; and corporate and other.

Share on Social Networks: